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Abstract
A potential strategy for diagnosing lung cancer, the leading cause of cancer-related death, is to identify metabolic
signatures (biomarkers) of the disease. Although data supports the hypothesis that volatile compounds can be detected in
the breath of lung cancer patients by the sense of smell or through bioanalytical techniques, analysis of breath samples is
cumbersome and technically challenging, thus limiting its applicability. The hypothesis explored here is that variations in
small molecular weight volatile organic compounds (‘‘odorants’’) in urine could be used as biomarkers for lung cancer. To
demonstrate the presence and chemical structures of volatile biomarkers, we studied mouse olfactory-guided behavior and
metabolomics of volatile constituents of urine. Sensor mice could be trained to discriminate between odors of mice with
and without experimental tumors demonstrating that volatile odorants are sufficient to identify tumor-bearing mice.
Consistent with this result, chemical analyses of urinary volatiles demonstrated that the amounts of several compounds
were dramatically different between tumor and control mice. Using principal component analysis and supervised machine-
learning, we accurately discriminated between tumor and control groups, a result that was cross validated with novel
test groups. Although there were shared differences between experimental and control animals in the two tumor models,
we also found chemical differences between these models, demonstrating tumor-based specificity. The success of these
studies provides a novel proof-of-principle demonstration of lung tumor diagnosis through urinary volatile odorants. This
work should provide an impetus for similar searches for volatile diagnostic biomarkers in the urine of human lung cancer
patients.
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Introduction
Lung cancer is the leading cause of cancer-related deaths
throughout most of the world [1]. The only treatment that that
achieves a high rate of cure is surgical resection of early disease
(before metastatic spread occurs). Since only about 25% of cases
are diagnosed at this early stage, effective early diagnostic
techniques are urgently needed.
Aggressive and early chest imaging of high risk patients is
emerging as the dominant approach to early diagnosis, although
large studies to validate this approach are still ongoing [2,3,4].
Unfortunately, although imaging is quite sensitive, it is also
relatively non-specific. Recent studies have shown that between
5–26% of high risk smoking patients have detectable lung nodules
by CT screening, however only an average of about 4% (with a
range of 2–11%) of these nodules are malignant [5]. Clearly
surgical resection of all of these nodules is neither practical nor
desirable. Approaches to determine which nodules should be
removed are thus needed. One attractive strategy would be to
combine a sensitive imaging technique with a biomarker of lung
cancer to increase specificity [6,7,8]. Because the incidence of lung
cancer in this ‘‘nodule population’’ is significantly higher than in
current or former smoking populations, biomarkers in this context
would not require the extremely high sensitivities and specificities
needed for population screening. Another use for such a
biomarker might be to follow the course of the tumor after
treatment.
With the development of high-throughput techniques for
biomarker discovery [9], the field of lung cancer biomarkers has
recently expanded substantially. Current biomarker candidates
from blood, sputum, and urine include many classes of molecules
including proteins, tumor antigens, anti-tumor antibodies, cell
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phenomena such as hyper-methylated DNA, RNA, and specific
gene expression [10]. However, no biomarker identified to date
has been shown to have adequate sensitivity, specificity and
reproducibility to be considered sufficient for use to detect and
monitor lung cancer development.
Another class of biomarkers for lung cancer could be small
molecular weight volatile organic compounds. These molecules,
which can be perceived as odors (especially by animals), have been
shown to function as ‘‘signatures’’ that convey social, emotional
and health information to other members of the species [11].
There might be two sources of volatile markers in lung cancer
patients. Studies have shown that lung cancer cell lines can release
specific volatile organic compounds in vitro [12]. The presence of a
growing tumor could also induce specific metabolic or nutritional
changes that could alter the production or release of such
compounds [6].
The ‘‘volatile hypothesis’’ for lung cancer has led to a number of
studies examining the utility of analyzing these compounds in
exhaled breath using either animals (such as dogs) [13] or
sophisticated biochemical techniques [14,15]. Some of these
studies have shown promise. For example, a recent study from
the Chen group [16] using solid phase micro-extraction followed
by gas chromatography showed that 1-butanol and 3-hydroxy-2-
butanone were found at significantly higher concentrations in the
breath of lung cancer patients compared to controls. Dragonieri et
al. used an ‘‘electronic nose’’ and were able to discriminate
patients with lung cancer versus those with chronic obstructive
lung disease with relatively high sensitivity and specificity [17].
Unfortunately, collecting, handling, storing, concentrating and
analyzing breath samples is cumbersome, technically challenging,
and may thus not be easy to apply widely. A partial solution to
these problems would be to use a much more convenient source of
volatiles, such as urine samples although urine, like breath, will
include not only endogenous volatiles but also exogenous ones
from sources such as diet and the environment. In this regard,
Willis et al. (2004) reported that dogs could be trained to
distinguish patients with bladder cancer on the basis of urine odor
more successfully than would expected by chance alone [18].
Unfortunately, a follow-up study by Gordon et1 al. [19] was
unable to reproduce these findings in urine samples from patients
with breast and prostate cancer.
Based on these considerations, the hypothesis explored in this
paper is that variations in small molecular weight volatile organic
compounds (‘‘odorants’’) in urine could be used as biomarkers for
lung cancer. One of the primary difficulties in attempting to
initially identify volatile biomarkers from human patients is the
vast variation that can be due to uncontrolled variables such as
genetic and dietary differences, personal care product usage, and
other environmental variables that can impact on body odor
volatiles. The observation that dogs can apparently filter out these
potential distractions and focus on the disease signature (see above)
suggests that potentially useful biomarkers may exist.
In light of these challenges, we elected to pursue a more highly
controlled animal model approach [20,21] where many of the
variables that make patient work so difficult can be controlled
(Figure 1A). Our strategy was to first demonstrate that mice can be
trained to discriminate urine samples from mice with tumors from
control mice by odor alone. Once we had established this was
possible, we then employed metabolic profiling (solid-phase-
microextraction, followed by gas chromatography coupled with
mass spectrometry) to show we could identify specific patterns of
volatiles in urine that could distinguish tumor-bearing mice from
control animals.
Results
Mouse Models of Lung Cancer
Lung tumors derived from mouse cell lines have similarities in
morphology, histopathology, and molecular characteristics with
human lung adenocarcinomas and can serve as useful first models
[22]. We used two mouse lung cancer cell lines, LKR that was
derived from a transgenic animal expressing mutated Kras and
LLC, the Lewis lung cell carcinoma which arose spontaneously.
Tumors were induced by inoculating each of these cell lines into
different groups of mice (control mice were injected with the
vehicle, saline, on the same schedule). The tumor growth curves
for these two cell lines showed similar patterns (Figure 1B). Based
on tumor growth curves, we collected urine samples that spanned
stages of tumor growth for bioassay and for later chemical
analyses.
Olfactory Detection of Urinary Odor
We trained sensor mice (see methods) to discriminate between
the odors of mouse urine samples collected from LKR-injected
mice with large tumors (Days 25–37 post cell injection) compared
to genetically identical control mice without tumors. When this
was successful, we tested to determine whether this learning
generalized to earlier stages of tumor development. As shown in
Figure 1C-i, the trained mice successfully distinguished between
urines collected from mice with tumors at 25–37, 15–20 and 9–14
days post injection but did not generalize to tumors at very early
stages (Days 1–7). Next, we further trained these same sensor mice
using urines collected on Days 15–24 post injection. Although
these mice generalized this training to novel samples collected
from mice with tumors the same size, they did not do so for urines
collected on Days 9–14 or 1–7 (Figure 1C-ii). Control experiments
verified that trained mice did not distinguish between injected and
uninjected mice prior to injections, demonstrating that there was
no bias in the original mouse urine or the Y-maze apparatus.
To investigate the generality of this result, we trained a separate
group of sensor mice to discriminate urines of mice with- and
without LLC-induced tumors. The pattern of results was almost
identical to that with LKR-induced tumors (Figure 1C-iii).
We next asked whether the odors associated with the LKR and
LLC tumors were perceptually similar, by testing the trained mice
on urine samples collected from tumor-bearing vs. control mice
from the animal model different from the one that they had been
trained on. That is, we asked whether mice trained to discriminate
urines of mice with and without LKR-induced tumors would
recognize (generalize this response to) LLC tumor-bearing mice
and vice versa. The answer was in the affirmative (Figure 1C-vi
and -v). These results show that tumors induced by these cancer
cell lines produce common (although not identical; see below)
volatile biomarkers that can be recognized by the olfactory systems
of mice.
Characterization of Urinary Volatile Compounds
We next characterized the nature of chemical variation
distinguishing mice with the tumors from those without by
analyzing urinary volatile compounds with solid-phase-microex-
traction, followed by gas chromatography coupled with mass
spectrometry. From the typical total ion chromatograms (TICs) a
large diverse set of peaks could be distinguished (Figure S1). Forty
seven peaks were selected for identification from the TICs based
on their having sufficiently large peak heights and non-overlapping
TICs as determined by visual inspection. As can be seen in Table 1
and S1, the peaks were comprised of a variety of chemical
structures and are potentially involved in several biological
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none, 3,4-dehydro-exo-brevicomin and 2-sec-butyl-4,5-dihydrothia-
zole, 6-hydroxy-6-methyl-3-heptanone, b-farnesene [23]). Also
identified were compounds previously reported in human urine
(nitromethane, dimethyl sulfone, o-toluidine, 2-ethylhexanoic acid
[24]).
We next used quantitative analyses of these 47 peaks to
determine if mice with and without experimentally-induced
tumors could be distinguished. Variation in the raw peak heights
clearly showed differences in the relative amounts of various
compounds based on the presence or absence of tumor and
cancer types (Figure 2A and Figure S2). We observed relatively
consistent changes for many peaks and for both tumor groups
with the most common pattern being a decreased production
(down-regulation) in the tumor groups and either an increased
production (up-regulation) or negligible change in the placebo
groups (Figure S3). For example, peak 13 (5-hepeten-2-one) was
down-regulated dramatically as a consequence of tumor pre-
sence (Figure 2B). Thus, an overall down-regulation of volatile
compounds may be a common feature of tumor growth. How-
ever, there were other patterns of change for a minority of
Table 1. Selected peaks and their identifications.
No. Cell lines with p,0.0001 Compounds




11 LLC unkown 2 compounds
13 LKR 5-hepten-2-one (E or Z)
18 LKR and LLC 2-acetyl-1-pyrroline
19 LKR and LLC 2-isopropyl-4,5-dihydrothiazole
22 LKR and LLC 2-sec-butyl-4,5-dihydrothiazole
27 LLC 6-hydroxy-6-methyl-3-heptanone
33 LKR o-toluidine
37 LLC 2-ethyl hexanoic acid
45 LKR N-phenyl formamide
doi:10.1371/journal.pone.0008819.t001
Figure 1. Tumor growth curves and urine collection times for bioassays and the results of bioassay. (A) Overview of experimental
procedure. We employed mouse olfactory guided behavior (left) and metabolomic (right) approaches. (B) LKR cells and LLC cells were injected
subcutaneously into the flanks of adult male mice and tumor size was measured weekly thereafter. Each time point shows the mean6SEM tumor
size. Solid line: actual data; Dotted line: curve fitted with cubic function; LKR: y=0.092*x
3 2 2.8*x
2+38*x 2 18, LLC: y=0.16*x
3 2 0.83*x
2+3.5*x 2 4.
Mouse urine was collected individually once a day and was used for chemical analysis and for bioassay during the periods indicated: For LKR - Days
15224 and 25237 for training and Days 227, 9214, 15220, and 25237 for generalization; For LLC - Days 17226 for training and Days 128, 9216,
and 17226 for generalization. (C) Box plot of generalization scores for bioassay and the correlations among tests. Blue boxes represent the lower and
upper quartiles. The red horizontal bar in each box indicates the median. The dotted line represents the range of observations. The plus (+) marks
extreme outlier observations. *;P,0.01, **;P,0.001, ***;P,0.0001 compared to the null hypothesis of a 50% generalization score. From left, LKR-
trained mouse urine generalization to LKR mouse urine (Training 1, Figure 1C-i); LKR- trained mouse urine generalization to LKR mouse urine (Training
2, Figure 1C-ii); LLC-trained mouse urine generalization to LLC mouse urine (Figure 1C-iii); LKR-trained mouse urine generalization to LLC mouse urine
(Figure 1C-iv); LLC-trained mouse urine generalization to LKR mouse urine (Figure 1C-v).
doi:10.1371/journal.pone.0008819.g001
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analyzed. Vertical axis indicates intensity (amount) of TIC; vertical lines around mean indicate SEM at each sampling point. Blue represents early stage
whereas red represents late stage. Horizontal axis indicates retention time. (B) Bar plot of intensity of 4 illustrative peaks selected from the 47 peaks
analyzed. Mean peak intensity is plotted at each peak. Red bars represent tumor groups; blue bars represent control groups. A pale blue background
indicates a significant difference at P,0.0001 between tumor and control groups. (C) Raw intensity of 47 analyzed peaks obtained by subtracting the
early period from the later period (n=25 for each of the 4 groups). Darker grey means the peak increased following tumor development whereas the
lighter grey means the peak decreased following tumor development.
doi:10.1371/journal.pone.0008819.g002
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hexanoic acid) was elevated in both tumor groups. Changes in
other peaks depended on cancer types (and/or mouse strain).
Peak 29 (Acetophenone) was down-regulation in the LKR-tumor
group and up-regulation in LLC-tumor group whereas peak 33
was down-regulation only in LKR tumor group. The image array
plot (Figure 2C) clearly shows the overall differential effects of
tumor growth.
Discrimination of Tumor and Placebo Groups
We next proceeded to metabolomic profiling to statistically
discriminate between groups and to identify characteristic peaks.
To this end, we combined two different approaches: principal
component analysis (PCA) and support vector machine (SVM).
The first, PCA, allows the structure in a dataset to dictate the
separation of samples into clusters based on overall similarity in
peak values without prior knowledge of sample identity. Plots of
PCA scores calculated from the normalized values of the 47 peaks
showed a distinctive separation of the chemical profile between
tumor groups and placebo groups in both cancer cell lines
(Figure 3A and 3B). Second, a supervised machine-learning
approach based on the SVM was employed to determine the
boundary between tumor groups and placebo groups. This
algorithm considered the first two principal components, PC1
and PC2, to create descriptions of samples in this high-
dimensional space, and then defined a hyperplane that best
separates samples from the two classes. The SVM classifier
successfully separated the samples into tumor and placebo
categories (displayed in the fine contour with color of blue to
red in Figure 3A and 3B). The SVM successfully classified most
individuals giving a classification accuracy of 94% with a
sensitivity of 88 % and specificity of 100% (LKR) and an accuracy
of 94% with a sensitivity of 100% and specificity of 88% (LLC).
Notably, only 3 of the 50 individual mice in our test set were
misclassified. Thus, the selected peaks contain chemical features
distinguishing tumor from placebo mice.
Cross Validation and Essential Combination of Peaks
To validate these analyses, we employed a 10-fold cross
validation method by using all 25 samples. For further analysis,
we selected 11 peaks from the original 47 peaks that differed
between tumor and placebo groups with a P,0.0001 (Table 1).
We trained the SVM classifier by applying all logically possible
combinations without repetitions from these 11 peaks for each of
the two model systems (LKR and LLC). The generalization
performance of the SVM classifiers employing different sets of
peak clusters was illustrated in receiver operating characteristic
(ROC) space. No single peak successfully classified with an
accuracy of greater than 95%. However, classification with several
pairs of peaks resulted in an accuracy of up to 9862% for LKR
and 100% for LLC (Table 2-i,-ii and Table S2, Figure S4),
confirming that better generalization relies upon a combination of
peaks. In further analyses (data not shown) we found that SVM
had superior performance to Fisher Discriminant Analysis, which
used unsupervised learning methods. Thus, characteristic peak
clusters can reliably differentiate tumor groups from placebo
groups and may have diagnostic potential.
To assess the generalization power of the peak clusters to a
novel group, we created independent training sets (13 of the 25
samples) and test sets (remained 12 samples). The SVM classifiers
trained with the 11 selected peak clusters of the training set
generated a best combination of peaks having accuracies of 95%
for LKR and of 100% for LLC to test sets (Table 2-iii,-v and Table
S3, Figure S5).
Although LKR and LLC cell lines are different model systems
and they were injected into different inbred mouse strains (which
themselves likely differed in body odors), our behavioral studies
suggested that they shared common odors indicative of the
presence or absence of tumors. This was also found to be the case
in the metabolomic analyses. The group of peaks (the cluster) that
best predicted LLC status from LKR data as determined by SVM
(Table 2-iv) had an accuracy of 98%. Conversely, the group of
peaks that best predicted LKR from LLC (Table 2-vi) had an
Figure 3. Separation of tumor and placebo groups based on PCA scores using SVM. Separation of tumor and placebo groups by Principle
Components Analysis (PCA) and its boundary determination by Support Vector Machine (SVM) are shown in A (LKR) and B (LLC). Circles represent
individuals of tumor groups and triangles represent individuals of placebo groups (Support vectors: solid circles and triangles). The background
contour color, ranging from red to blue, indicates the class probability for different regions of the plane.
doi:10.1371/journal.pone.0008819.g003
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common to these two sets of predictive clusters. Classification by
other peak clusters also generated high diagnostic accuracy (95%)
with substantial diagnostic potential (Figure S6).
Interactive Effect of Tumors and Cell Lines
Even though there were commonalities between the two tumor
models, further statistical analyses also demonstrated that the
effects of the two tumor models on metabolic profiles were not
identical. The interactions between two different cell lines (LKR
and LLC) and tumor vs. placebo was analyzed with 2-way analyses
of variance (tumor and placebo groups for each of the two tumor
models) for each of the 47 peaks (Figure 4 and S7). A significant
interaction indicates tumor specificity. Of the 47 separate analyses,
the interaction w’as significant (P,0.05) in 11 cases (Table S3). To
control for false positives due to testing 47 peaks, we restricted
consideration to 4 peaks (No. 1, 7, 29, and 33) with P,0.002.
These interactions are illustrated in Figure 4 where, for example,
peak 29 shows no difference between tumor and placebo
(P=0.0387) but a large difference between tumor models
(P=0.0002). There is sufficient specificity to distinguish between
the volatile profiles of the two tumor types.
Discussion
Identification of volatile biomarkers in urine for disease
diagnosis is an area of great promise, however it is based on
limited prior human research. The data in this paper are
consistent with the hypothesis that diagnostically useful volatile
compounds are produced in patients with lung cancer and
secreted into the urine, thus providing support for this diagnostic
approach in the context of lung cancer.
Specifically, our studies showed that animal olfaction in species
like the mouse (that has a sensitive olfactory system [25,26]), can
have diagnostic success in detecting lung cancer signatures in
urine. More importantly, we were able to mimic this ability using
bioanalytic techniques. This suggests it will be possible to create a
biomimetic sensor based on the knowledge of olfactory system
for screening diagnostic odorants that could be practical for
widespread applications [27,28,29,30]. Indeed, genetically engi-
neered yeast expressing an olfactory receptor and its signal
transduction system have been shown to be capable of detecting
2,4-dinitrotoluene, a compound diagnostic of explosives [31].
Artificial olfaction with a polymer epithelium and model glomeruli
could detect odorants thereby mimicking a biological olfactory
system [32]. Ultimately, such sensors could lead to the development
Figure 4. Interactions between tumor type and tumor stage.
Normalized intensity (on the vertical axis) of the four peaks (A2D) in
which a two-way ANOVA indicated significant (P,0.002) interactions
indicating differentiation between the two tumor models. The
horizontal axis of each of the 4 panels (A2D) indicates the two stages,
early - prior to significant tumor development on the left and later -
after development of significant tumor size. Red: tumor, Blue: placebo,
Circle: LKR, Star: LLC.
doi:10.1371/journal.pone.0008819.g004
Table 2. Summary of highest scores of SVM classifiers.
Summary of highest scores of SVM classifiers
Numbers of Peaks Accuracy Sensitivity Specificity
i) LKR ten-fold CV mean sem mean sem mean sem
Nos. 7, 13, 22 98 2 97.5 2.5 100 0
Nos. 8, 13, 18, 19, 22, 45 98 2 100 0 95 5
ii) LLC ten-fold CV
Nos. 5, 11, 19, 37 (or 2, 4, 6, 19, 37) 100 0 100 0 100 0
iii) LKR to LKR (training, 13 samples; test, 12 samples)
Nos. 7, 8, 13 95 5.6 91.67 0 98.33 1.11
Nos. 13, 33, 45 (or 8, 13, 33, 45) 95 8.3 90 1.67 100 0
iv) LKR to LLC (training, 13 samples; test, 12 samples)
Nos. 13, 22, 33, 45 (or 7, 13, 19, 22, 33, 45) 98.33 1.67 100 0 96.67 3.33
v) LLC to LLC (training, 13 samples; test, 12 samples)
Nos. 2, 6, 19, 37 (or 4, 5, 19, 37) 100 0 100 0 100 0
vi) LLC to LKR (training, 13 samples; test, 12 samples)
Nos. 5, 11, 22, 27, 37 91.25 4.2 91.67 0 90.83 8.3
doi:10.1371/journal.pone.0008819.t002
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metabolic profiling (solid-phase-microextraction, followed by gas
chromatography coupled with mass spectrometry) is a viable
alternative that should be further explored.
The metabolic origin of many of the diagnostic biomarkers we
identified is not known and we could not identify common
chemical features. Instead, they had their origins in either a variety
of endogenous biochemical pathways or from environmental
(exogenous) sources. These latter compounds (e.g. o-toluidine, and
2-ethylhexanoic acid) are unlikely to be diagnostically useful.
Among the endogenous metabolites, 2-heptanone, a pheromone,
is reported to increase in concentration in stressed rats, and has
been observed in human urine [33]. 6-hydroxy-6-methyl-3-
heptanone has also been previously identified in mouse urine
although we can find no report of this compound in human urine.
The observed variation of ketones as a function of tumor growth
suggests that ketogenesic pathways may be involved in these
models of lung cancer. Further research would be required to
determine which of these diagnostic metabolites are of tumor
origin and which originate from normal metabolic processes and
are either down- or up-regulated by the tumors.
The common down-regulation we observed following tumor
development in many compounds is noteworthy. Most biomarkers
reported by other investigators have been up-regulated. One
explanation for these different findings may reside with detection
strategies employed by others to identify biomarkers. In some
investigations there may be a bias toward a search for novel (and
therefore up-regulated) biomarker compounds whereas our
methods had no such bias. Another possibility is that this frequent
down-regulation results from complex effects of the tumor on the
animal’s metabolism.
Although SVM found clusters of peaks that predicted between
the two models of cancer (LKR to LLC and vice versa: Table 2)
with high accuracy, the clusters were mainly different for
prediction in the two directions. This result appears to be
inconsistent with the animal training studies that indicated that
mice trained to discriminate in one of the tumor models
generalized this learned response without further training to the
other model. This implies that there should be a set of volatile
compounds (odorants) common to the two models that differen-
tiate tumor from non-tumor mice. One likely explanation for this
apparent anomaly is that the combinations of volatile components
that we have identified with SVM classifiers are not the same ones
that the mice are cueing in on during training and testing; perhaps
there are other components in common with the two models that
we have not yet identified. If this is the case, one of the next
challenges will be to identify these novel biomarkers. Alternatively,
we note that there was one compound that was common to
prediction in both directions (#22) and we cannot exclude the
possibility that it was this compound the mice used to make the
distinction in both cases.
An important consideration for any practical diagnostic tool is
its ability to discriminate among different types of disease.
Although the two models of lung cancer clearly have similarities
in volatile profiles, they also have sufficient differences that they
can be discriminated in metabolomic analyses (Figure 4). This
ability to discriminate between closely related mouse models of
lung cancer implies that specific cancer types may be amenable to
diagnostic differentiation through analyses of volatile profiles as
illustrated in the current research.
Future work with animal models could proceed along three
convergent lines. First, it is important to monitor the develop-
mental changes in markers at earlier stages of tumor development.
Not only is this relevant to determining how early diagnostic
markers can be detected but it could throw light on potential
mechanisms underlying changes in volatiles as a consequence of
the tumor progression. Second, a variety of different tumor types
should be investigated in addition to the two closely related ones
described here. This could also provide important clues as to
mechanism. Third, in vitro studies on tumor cells will be crucial in
understanding mechanisms.
In summary, we were able for the first time to identify volatile
chemical signatures in urine of mouse models of lung cancer using
rigorous experimental behavioral and analytic techniques. The
importance of this study is that it establishes the feasibility of using
urinary volatiles to detect lung cancer. The ability to easily collect
and store urine samples will be a major advantage of this approach
over analyzing volatile in exhaled breath. Although this study has
raised many questions about the identity and source of the
compounds detected in our mouse models, we are not planning to
pursue this direction. Instead, we view this study as an important
proof of principal for the value of studying urine volatiles using
biochemical and bioinformatic techniques in the diagnosis of
human lung cancer (and perhaps other cancers). Accordingly, we
have begun clinical studies with human patients. These studies
will address key questions about sensitivity, specificity, the size
of tumors that can be accurately detected, the mechanisms
underlying the observed changes in volatile profiles, the ability to
generalize among different types of lung cancers, and the impact of
current or former smoking.
Materials and Methods
Lung Cancer Cell lines
The Kras-induced murine lung cancer (LKR) and Lewis lung
cell carcinoma (LLC) cell lines were purchased from the ATCC
(American Type Culture Collection, Manassas, VA). LKR cells
were derived from explants of a pulmonary tumor from an
activated K-rasG12D mutant mouse grown in Dr. Tyler Jacks’
Laboratory at M.I.T. [34]. Cells were cultured and maintained
in high glucose DMEM (Mediatech, Washington, DC) supple-
mented with 10% fetal bovine serum (Georgia Biotechnology,
Atlanta, GA), 2 mmol/L glutamine, and 1% penicillin/strepto-
mycin [35].
Flank Tumor Model Mice of LKR and LLC Cell Lines
To create peripheral tumors 100 mLo f1 610
6 LKR cells were
injected in the flanks of male C57BL/6J6129P3/J F1 hybrid
mice (group 1: n=27; group 2: n=22: LKR tumor groups). For
control purposes, 100 mL of saline was injected in individuals of
LKR-placebo group (n=26). In the second model, 100 mLo f
1610
6 LLC cells were injected in the flanks of 8-week-old
male C57BL/6J mice (n=32, LLC-tumor group) and for control
mice 100 mL of saline was injected into same strain individuals
of the LLC-placebo group (n=31). Tumors were measured
weekly beginning 1 week after injection with a digital caliper
and volumes were estimated using the formula 3.146[largest
diameter6(perpendicular diameter)
2]/6. The measured points
were fitted with a cubic function implemented in MATLAB. All
mice used in these experiments were maintained on a 12:12 h
light:dark cycle. All mice were given food and water ad libitum
throughout the experimental period. Tumor-injected mice were
euthanized when it appeared that the tumor burden induced
discomfort. The mice were cared for in accordance with the
Guide for the Care and Use of Laboratory Animals and the
experimental protocols were previously approved by the Institu-
tional Animal Care and Use Committee in Monell Chemical
Senses Center (Approval number: 1113p).
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Voided mouse urine was collected individually once a day, 5
days per week by gentle abdominal pressure into a sterile glass
tube [36]. Immediately, urine samples were frozen at 220uC and
retained until needed for experiments.
Sensor Mice and Behavior Assessment in the Y-Maze
Apparatus
Mice (Male C57BL/6, n=6; female C57BL/6 H-2
b, n=1) were
trained in a Y-maze apparatus to discriminate between urines of
tumor bearing mice compared with placebo (non-tumor bearing)
mice [37]. Briefly, the two arms of the maze were scented by air
currents conducted through chambers containing freshly-thawed
urine (0.3–0.4 ml placed in 3.5-cm-diameter Petri dishes). For
training and testing in the Y-maze, gates were raised and lowered in
a timed sequence of upto 48 consecutivetrials,paired urinesamples
(tumorvs.placebo)beingchangedforeachtrial. Duringthe training
session, water-deprived sensor mice for 23hr were rewarded with a
drop of water for each correct response. After successful training
(.80% correct scores), unrewarded (generalization) trials were
interspersed at an average frequency of one in four to accustom the
mice to occasional absence of reward.
For one group of trained mice (n=7), training samples consisted
of urine collected 25–37 days after either LKR cell injections
(LKR tumor mice) or placebo injection (LKR-placebo mice)
(Figure 1B). Four mice were reinforced in the Y-maze when they
chose the urine scent of LKR tumor mice over LKR placebo mice
whereas the other 3 trained mice were reinforced for the opposite
choice. Within 14 days, all mice were responding correctly at
.80% accuracy. At this point generalization trials with novel
samples were introduced (see next paragraph). A second group of
trained mice (female C57BL/6, n=3; female C57BL/6 H-2
k,
n=1) were trained on LLC tumor vs. LLC placebo urine samples
collected on days 17–26 post-cell or placebo injections. Here 2
mice were reinforced for LLC tumor and the other two were
reinforced for LLC placebo.
Mice were then tested in generalization trials with novel urine
samples (by blind testing) that were collected from LKR
experimental (tumor bearing) and LKR placebo mice during days
2–7, 9–14, 15–20, and 25–37 and for LLC experimental and
placebo mice during days 1–8, 9–16, and 17–26 (Figure 1B). To
test for detection of urine odor changes at earlier stages of tumor
development, LKR-trained mice were retrained on samples
collected on days 15–24 of LKR and then were given a series of
generalization tests. Additionally, LKR trained mice were given a
series of generalization tests with LLC tumor vs. control samples
(these animals never having been trained on LLC) and,
reciprocally, LLC-trained mice were with LKR samples. The
animals were maintained on a 12 hr light/dark cycle and tested
during their light period.
Extraction of Mouse Urinary Volatile Compounds by
Solid-Phase-Microextraction
We chemically analyzed 25 samples of urines for each group at
two time points: early stage (Days 1–3) and terminal stage (Days
34–40) of the LKR-tumor and -placebo groups and, in parallel,
early stage (Days 1–3) and terminal stage (Days 24–27) of the LLC-
tumor and -placebo groups. One hundred ml of mouse urine was
placed in a 4-ml glass vial and the volatiles in the headspace were
extracted for 30 min at 40uC using a Solid-Phase-Microextraction
(SPME) fiber (2-cm long, 30 mm carboxen, 50 mm divinyl benzene,
polydimethyl siloxane, Supelco Corp, Bellefonte, PA). No salt
addition or pH adjustment was performed on the mouse urine.
Gas Chromatography and Mass Spectrometry
The SPME fiber with absorbed volatile compounds was inserted
into the injection port of Thermo-Finnigan Trace GC/MS
(Thermo Electron, San Jose, CA) system and desorbed for 5 min
at 230uC. The Trace GC/MS was equipped with a Stabilwax
column (30 M60.32 mm with 1.0 m coating; Restek, Bellefonte,
PA) which was used for separation and analysis of the desorbed
volatiles. We employed the following chromatographic protocol for
separation before MS analyses: 60uC for 4 min, then programmed
at 6uC/min to 230uC with a 40-min hold at this final temperature.
Column flow was constant at 2.5 ml/min. The injection port was
held at 230uC. Operating parameters for the mass spectrometer
were as follows: ion source temperature, 200uC, ionizing energy at
70 eV; scanning frequency was 2/s from m/z 41 to m/z 400. Peak
identification was accomplished through manual interpretation of
spectra and matching against the NIST’02 library and comparison
with commercially available standard samples when available.
Data Processing of Raw GC/MS Chromatogram
RawGC/MS chromatograms werepre-processed using methods
similar to those described elsewhere [38]. Briefly, components
were detected simultaneously across all samples, quantified, log-
transformed, and then normalized for differences in overall
intensity levels with MATLAB. Forty seven total ion peaks from
the total ion chromatogram were selected, all of which are shared
by each animal in every group, and the heights were quantified.
To eliminate the effect of the treatment term from the first day to
last day that may occur in both experimental and control groups
we defined the change in the production level of volatile
compounds as: Ri=tHi–eHi (i=1, 2,…, 47), where tHi denotes
the maximum height of each peak at the terminal stage (i.e. days
25–37 for LKR and 17–26 for LLC while eHi denotes the
maximum height of each peak at the early stage (Days 1–3).
Thus, the subtracted value (Ri) represents ‘‘the term effect’’ for
the placebo groups (LKR(–) and LLC(–)) and ‘‘the term plus the
tumor effect’’ for tumor groups (LKR(+) and LLC(+)) (Figure 2B).
The subtracted value was normalized for data processing.
Two-Way Analysis of Variance
We used two-way analysis of variance to assess the effects of
lung cancer and tumor development on relative subtracted value
for each compound. The following statistical model [39] was fit
separately for each compound to assess the effects of lung cancer
and tumor development on relative subtracted value:
Yijk~mztizbjz tb ðÞ ijzeijk
where Yijk is normalized subtracted value, m is the overall average,
ti is the relative effect of tumor effect i (i=1, 2 corresponding to
tumor and placebo), bj is the relative effect of lung cancer type
j (j=1, 2 corresponding to LKR and LLC), and tb ðÞ ij is an
interaction effect describing the extent to which the lung cancer
effectti depends onstraineffectbj. Asignificantinteraction suggests
that mice of different lung cancer types respond metabolically
differently to tumor development. The random error term eijk
captures all other unexplained variation, and is assumed to have
mean 0 and variance s2.
Principal Component Analysis and Boundary
Determination by Support Vector Machine
Linear principal component analysis (PCA) was employed to
examine the projection between two classes (e.g. LKR(+) vs.
Odor Signatures of Lung Cancer
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the two dimensional space. The first principal component (PC1)
accounts for as much of the variability in the data as possible, and
each succeeding component accounts for as much of the
remaining variability as possible.
For capturing the nonlinear boundaries between two classes
(e.g. LKR(+) and (2)) as well as for understanding factors
responsible for the group separation identified by PCA, we
employed support vector machine (SVM) classifiers, which have
been used with considerable success in a variety of fields
including computational biology [40]. SVM finds an optimal
hyperplane that separates two classes in high dimensional pro-
jected feature space. SVM maximizes the margin of separation
between two classes to find a separating optimal hyperplane
fx ðÞ ~
P
wixizb~w0xzb, where w is the p-dimensional vector
perpendicular to the hyperplane, b is the bias, i is the number
of peaks. The SVM finds w=(w1, w2,… ,wp)’ minimizing
(1/2)||w||
2 subject to the constraints yi(w0xzb)$1, "i=1, …,
n, where yi=+1 or 21 depending on the class. When the training
data are not linearly separable, SVM minimizes (1/2)||w||
2+C
gji subject to the constraints yi(w0xzb+ji)$1, "yi=+1;
yi(w0xzb2ji)$1, "yi=21; ji$0, "i. The ji is the slack variable.
To realize this projection, we have used the Gaussian (also known
as RBF) kernels of Kernlab package of R (http://www.r-project.
org/), Spider MATLAB toolbox (http://www.kyb.tuebingen.
mpg.de/bs/people/spider/) which implements linear function




initialized radial basis function (RBF) dot with parameter s=0.9.
The performance of the SVM classifiers was assessed by con-
sidering the number of correctly classified (true positives, tp; true
negatives, tn) and incorrectly classified (false positives, fp; false
negatives, fn) cases in the testing set. Sensitivity (se) was defined as
the probability of a true positive, se=tp/(tp+fn); specificity (sp) as
of a true negative, sp=tn/(tn+fp); and accuracy (ac) as the
proportion of correct classifications, ac=(tp+tn)/(tp+fp+tn+fn).
True positive rate (se) and false positive rate (1–sp) was plotted
onto a receiver operator curve (ROC) space to perform diagnostic
accuracy of SVM classifier. The error rate of the classifier is
defined as the average number of misclassified samples, i.e. the
sum of off-diagonal elements of the confusion matrix divided by
the total number of objects.
Ten-Fold Cross Validation and Generalization with
Classifier
We used 10-fold cross validation to estimate diagnostic accuracy
using 11 peaks that were selected based on the criterion that they
were different between the tumor vs. control group (for LKR or
LLC) at P,0.0001 (Table S1). We used 10-fold cross validation to
estimate diagnostic accuracy using 11 peaks that were selected
based on the criterion that they were different between the tumor
vs. control group (for LKR or LLC) at P,0.0001 (Table S1).
In the first approach, the original 25 sample data sets from mice
with tumors (e.g. LKR(+)) and the control mice (e.g. LKR(2)) were
eachrandomly splitinto 10sub-samples,eachsub-sample consisting
of 1–3 mice. The SVM classifier was then trained on 9 (10 minus 1)
of the subgroups with a single subgroup being retained as the test
sample. This cross-validation process was repeated 10 times (the
folds), each of which has a different validation test group so that
each sub-sample serves one time as a test sample. The resulting
values for each of the folds were averaged to produce mean values
for accuracy, sensitivity, and specificity (Figure S4, Table S2).
In a second approach, to determine a robust estimation of the
generalization capability of classifiers for unknown samples, we
randomly assigned 13 samples to a training set and left the
remaining 12 samples for a test set (e.g. 13 LKR(+) and 13
LKR(2) were the training sets and 12 LKR(+) and 12 LKR(2)
were the test sets). Using these sets, we determined the SVM
classifiers using training sets made up of all logically possible
combinations (combinations without repetition) of the selected 11
peaks (n=2047 possible combinations). The classifiers were
evaluated for accuracy, sensitivity, and specificity. In addition, to
determine the predictive values across the two tumor cell lines (i.e.
how predictive LKR is for LLC and vice versa), two additional
tests were conducted. In one, the training sets were made up of
LKR(+) and LKR(2) (n=13 mice each) and the test sets were
made up of LLC(+) and LLC(2) (n=12 each). In the other this
procedure was reversed. The calculated scores for these analyses
were plotted in two dimensional spaces for sensitivity, and
specificity (Figure S5 and S6) and are summarized in Table 2
and Table S2. We plotted onto a receiver operator curve (ROC)
space to perform diagnostic accuracy of SVM classifier.
Supporting Information
Figure S1 Image plot of total ion chromatogram (TICs). Total
ion chromatograms of volatile compounds from urine samples
collected during the early and late stages of the two tumor groups
as well as parallel collections for the two placebo groups. TICs
were pre-processed (see methods and reference). A typical TIC is
shown in the top of (a) and the intensity is displayed as a colorized
belt at the bottom of (a). All of TICs are displayed for LKR (b) and
for LLC cell lines (c). The horizontal belt contains TICs from 25
animals. The horizontal axis represents retention time (later, far
right).
Found at: doi:10.1371/journal.pone.0008819.s001 (1.05 MB
PDF)
Figure S2 Comparison between early stage and late stage of
peaks. Forty-seven peaks were selected from the TICs for further
analysis. Vertical axis indicates intensity (amount) of TIC; vertical
lines around mean indicate SEM at each sampling point. Blue
represents the early stage whereas red represents the late stage.
Horizontal axis indicates retention time.
Found at: doi:10.1371/journal.pone.0008819.s002 (3.99 MB
PDF)
Figure S3 Bar plot of the intensity of the 47 peaks. Mean peak
intensity is plotted for each peak. Red bars represent tumor groups
whereas blue bars represent control groups. A pale blue
background indicates a significant difference at P,0.0001 between
tumor and control groups. It is possible to create a "bar code"
representing each individual mouse.
Found at: doi:10.1371/journal.pone.0008819.s003 (0.47 MB
PDF)
Figure S4 Classification performance in ROC space of paired
peaks. Each box (A-K) provides an overall visual representation of
ROC obtained from the ten-fold cross validation of LKR. Red
dots indicate mean sensitivity (vertical axis) and mean specify
(horizontal axis, 1-specificity) for each classifier. The number of
paired peaks are: A, 1; B, 2; C, 3; D, 4; E, 5; F, 6; G, 7; H, 8; I, 9;
J, 10; K, 11. Each box (L–V) provides an overall visual
representation of ROC obtained from the ten-fold cross validation
of LLC. Red dots indicate mean sensitivity (vertical axis) and mean
specify (horizontal axis, 1-specificity) for each classifier. The
number of paired peaks are: L, 1; M, 2; N, 3; O, 4; P, 5; Q, 6; R, 7;
S, 8; T, 9; U, 10; V, 11.
Found at: doi:10.1371/journal.pone.0008819.s004 (0.64 MB
PDF)
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peaks. Each box (A–K) provides an overall visual representation of
ROC obtained from generalization to the LKR test group by the
LKR training group. Red dots indicate mean sensitivity (vertical
axis) and mean specify (horizontal axis, 1-specificity) for each
classifier. The number of paired peaks are: A, 1; B, 2; C, 3; D, 4; E,
5; F, 6; G, 7; H, 8; I, 9; J, 10; K, 11. Each box (L–V) provides an
overall visual representation of ROC obtained from generalization
to the LLC test group by the LLC training group. Red dots indicate
mean sensitivity (vertical axis) and mean specify (horizontal axis,
1-specificity) for each classifier. The number of paired peaks are:
L, 1; M, 2; N, 3; O, 4; P, 5; Q, 6; R, 7; S, 8; T, 9; U, 10; V, 11.
Found at: doi:10.1371/journal.pone.0008819.s005 (0.67 MB
PDF)
Figure S6 Generalization performance in ROC space of paired
peaks. Each box (A–K) provides an overall visual representation of
ROC obtained from generalization to the LLC test group by the
LKR training group. Red dots indicate mean sensitivity (vertical
axis) and mean specify (horizontal axis, 1-specificity) for each
classifier. The number of paired peaks are: A, 1; B, 2; C, 3; D, 4; E,
5; F, 6; G, 7; H, 8; I, 9; J, 10; K, 11. Each box (L–V) provides an
overall visual representation of ROC obtained from generalization
to the LKR test group by the LLC training group. Red dots indicate
mean sensitivity (vertical axis) and mean specify (horizontal axis,
1-specificity) for each classifier. The number of paired peaks are:
L, 1; M, 2; N, 3; O, 4; P, 5; Q, 6; R, 7; S, 8; T, 9; U, 10; V, 11.
Found at: doi:10.1371/journal.pone.0008819.s006 (0.70 MB
PDF)
Figure S7 Regulatory factor determined by two-way ANOVA.
Normalized intensity of subtracted peaks in a two-way ANOVA.
Red: tumor, Blue: placebo, Circle: LKR, Star: LLC.
Found at: doi:10.1371/journal.pone.0008819.s007 (0.41 MB
PDF)
Table S1
Found at: doi:10.1371/journal.pone.0008819.s008 (0.32 MB
PDF)
Table S2
Found at: doi:10.1371/journal.pone.0008819.s009 (0.31 MB
PDF)
Table S3
Found at: doi:10.1371/journal.pone.0008819.s010 (0.24 MB
PDF)
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